Skip to main content
Telix Pharmaceuticals Ltd logo

Telix Pharmaceuticals Ltd — Investor Relations & Filings

Ticker · TLX ISIN · AU000000TLX2 ASX Manufacturing
Open in API
Filings indexed 989 across all filing types
Latest filing 2020-09-20 Regulatory Filings
Country US United States of America
Listing ASX TLX

About Telix Pharmaceuticals Ltd

https://telixpharma.com/

Telix Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals, an approach known as 'theranostics'. The company utilizes targeted radiation to both image and treat various forms of cancer. Its extensive clinical pipeline and portfolio address key areas in oncology, including urologic (prostate and kidney), neurologic (glioma), and musculoskeletal cancers, as well as applications in bone marrow conditioning. Telix has secured global regulatory approvals for its prostate cancer imaging agent and supports its products with a robust global supply, manufacturing, and distribution network. The company is actively engaged in numerous clinical trials worldwide to expand its theranostic platform.

Recent filings

Filing Released Lang Actions
First patients dosed in Phase I study of APOMAB theranostic 2 pages 204.1KB
Regulatory Filings Classification · 95% confidence The document is a press release announcing the dosing of first patients in a clinical trial for a novel cancer theranostic by Telix Pharmaceuticals. It contains no financial data, no regulatory filings, no voting results, no management or board changes, no earnings or annual report content. It is a corporate announcement about a clinical trial milestone, not a financial or regulatory report. The document length is about 4963 characters, and it is clearly an announcement of a clinical development event. This type of document fits best under Regulatory Filings (RNS) as a general corporate announcement that does not fit other specific categories.
2020-09-20 English
Strategic Collaboration with Varian for Prostate Imaging 2 pages 216.3KB
Regulatory Filings Classification · 95% confidence The document is a press release announcing a strategic collaboration agreement between Telix Pharmaceuticals Limited and Varian Medical Systems for advanced prostate imaging. It discusses the terms of the collaboration, background on prostate cancer, and company information. There are no financial statements, regulatory filings, voting results, or management changes. The content is focused on a business partnership announcement rather than financial results, governance, or regulatory compliance. It is not a report, transcript, or detailed financial document. Therefore, the best fitting category is Regulatory Filings (RNS), as it is a general regulatory announcement that does not fit other specific categories.
2020-09-02 English
IRE Distribution Partnership for Prostate Cancer Imaging 2 pages 205.2KB
Regulatory Filings Classification · 95% confidence The document is a press release announcing a new exclusive distribution partnership agreement between Telix Pharmaceuticals and IRE Elit for a prostate cancer imaging product. It contains no financial statements, no regulatory filings, no voting results, no management or board changes, no earnings data, and no detailed financial or operational report. The content focuses on a commercial agreement and product distribution, which fits best under a general regulatory announcement category. The document length is about 5,097 characters, which is relatively short and does not contain detailed financial or operational data. Therefore, it is not an Annual Report, Interim Report, Earnings Release, or any other detailed financial report. It is not a report publication announcement either, as it does not mention any report being published or attached. The best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous announcements that do not fit other categories.
2020-08-31 English
FDA grants orphan drug designation for TLX102 2 pages 202.5KB
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Telix Pharmaceuticals Limited has been granted FDA Orphan Drug Designation for a novel therapy targeting multiple myeloma. It discusses the drug, its development, and the implications of the designation. There are no financial statements, no detailed financial performance data, no regulatory certifications, or voting results. The document is an announcement of a regulatory milestone related to drug development, not a financial report or management update. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is also not a legal proceeding or M&A activity. The content is a corporate announcement about a regulatory designation, which is best classified under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2020-08-30 English
Half Year Shareholder Update 34 pages 3.1MB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Telix Pharmaceuticals Limited Half-Year Shareholder Update' dated August 21, 2020. It contains detailed information about the company's clinical pipeline, commercial activities, financial dashboard for H1 2020, sales review, clinical trial statuses, COVID-19 impact, and regulatory submission statuses including EU Marketing Authorization and US NDA submission. The content is comprehensive and covers a half-year period with substantive financial data and operational updates. It is not a brief announcement or a presentation but a detailed report on the half-year performance and outlook. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2020
2020-08-20 English
Report for half-year to 30 June 2020 29 pages 965.3KB
Regulatory Filings
2020-08-19 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.